These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32869828)

  • 1. Driving antimalarial design through understanding of target mechanism.
    Calic PPS; Mansouri M; Scammells PJ; McGowan S
    Biochem Soc Trans; 2020 Oct; 48(5):2067-2078. PubMed ID: 32869828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
    McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimalarial effect of cell penetrating peptides derived from the junctional region of Plasmodium falciparum dihydrofolate reductase-thymidylate synthase.
    Chaianantakul N; Sungkapong T; Supatip J; Kingsang P; Kamlaithong S; Suwanakitti N
    Peptides; 2020 Sep; 131():170372. PubMed ID: 32673701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural plasticity of malaria dihydroorotate dehydrogenase allows selective binding of diverse chemical scaffolds.
    Deng X; Gujjar R; El Mazouni F; Kaminsky W; Malmquist NA; Goldsmith EJ; Rathod PK; Phillips MA
    J Biol Chem; 2009 Sep; 284(39):26999-7009. PubMed ID: 19640844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KBE009: An antimalarial bestatin-like inhibitor of the Plasmodium falciparum M1 aminopeptidase discovered in an Ugi multicomponent reaction-derived peptidomimetic library.
    González-Bacerio J; Maluf SEC; Méndez Y; Pascual I; Florent I; Melo PMS; Budu A; Ferreira JC; Moreno E; Carmona AK; Rivera DG; Alonso Del Rivero M; Gazarini ML
    Bioorg Med Chem; 2017 Sep; 25(17):4628-4636. PubMed ID: 28728898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
    Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
    Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular surveillance of anti-malarial resistance Pfdhfr and Pfdhps polymorphisms in African and Southeast Asia Plasmodium falciparum imported parasites to Wuhan, China.
    Jiang T; Cheng W; Yao Y; Tan H; Wu K; Li J
    Malar J; 2020 Nov; 19(1):434. PubMed ID: 33238987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational and experimental elucidation of Plasmodium falciparum phosphoethanolamine methyltransferase inhibitors: Pivotal drug target.
    Singh J; Vijay S; Mansuri R; Rawal R; Kadian K; Sahoo GC; Kumar M; Sharma A
    PLoS One; 2019; 14(8):e0221032. PubMed ID: 31437171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes.
    Sitali L; Mwenda MC; Miller JM; Bridges DJ; Hawela MB; Hamainza B; Mudenda-Chilufya M; Chizema-Kawesha E; Daniels RF; Eisele TP; Nerland AH; Chipeta J; Lindtjorn B
    Acta Trop; 2020 Dec; 212():105704. PubMed ID: 33002448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of pfdhfr and pfdhps mutations in Plasmodium falciparum associated with drug resistance among pregnant women receiving IPTp-SP at Msambweni County Referral Hospital, Kwale County, Kenya.
    Gikunju SW; Agola EL; Ondondo RO; Kinyua J; Kimani F; LaBeaud AD; Malhotra I; King C; Thiong'o K; Mutuku F
    Malar J; 2020 May; 19(1):190. PubMed ID: 32448228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and In Vitro Evaluation of Potential Plasmodium falciparum Leucyl Aminopeptidase Inhibitors.
    Chaudhary M; Singh V; Anvikar AR; Sahi S
    Curr Comput Aided Drug Des; 2016; 12(4):282-293. PubMed ID: 27449897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.
    Wadood A; Ghufran M; Hassan SF; Khan H; Azam SS; Rashid U
    Pharm Biol; 2017 Dec; 55(1):19-32. PubMed ID: 27650666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of molecular markers of sulfadoxine-pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan.
    Yaqoob A; Khattak AA; Nadeem MF; Fatima H; Mbambo G; Ouattara A; Adams M; Zeeshan N; Takala-Harrison S
    Malar J; 2018 Dec; 17(1):471. PubMed ID: 30558587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
    Chen W; Huang Z; Wang W; Mao F; Guan L; Tang Y; Jiang H; Li J; Huang J; Jiang L; Zhu J
    Bioorg Med Chem; 2017 Dec; 25(24):6467-6478. PubMed ID: 29111368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR, docking and ADMET studies of artemisinin derivatives for antimalarial activity targeting plasmepsin II, a hemoglobin-degrading enzyme from P. falciparum.
    Qidwai T; Yadav DK; Khan F; Dhawan S; Bhakuni RS
    Curr Pharm Des; 2012; 18(37):6133-54. PubMed ID: 22670592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoproteomics validates selective targeting of
    Giannangelo C; Challis MP; Siddiqui G; Edgar R; Malcolm TR; Webb CT; Drinkwater N; Vinh N; Macraild C; Counihan N; Duffy S; Wittlin S; Devine SM; Avery VM; De Koning-Ward T; Scammells P; McGowan S; Creek DJ
    Elife; 2024 Jul; 13():. PubMed ID: 38976500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico screening against wild-type and mutant Plasmodium falciparum dihydrofolate reductase.
    Fogel GB; Cheung M; Pittman E; Hecht D
    J Mol Graph Model; 2008 Apr; 26(7):1145-52. PubMed ID: 18037315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PfalDB: an integrated drug target and chemical database for Plasmodium falciparum.
    Kumar A; Agarwal N; Pant L; Singh JP; Ghosh I; Subbarao N
    Curr Drug Targets; 2014; 15(12):1089-93. PubMed ID: 25198774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania.
    Baraka V; Ishengoma DS; Fransis F; Minja DT; Madebe RA; Ngatunga D; Van Geertruyden JP
    Malar J; 2015 Nov; 14():439. PubMed ID: 26542942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.